Jul 3 |
Merck: Among The Best Health Care GARP Plays Today
|
Jul 2 |
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
|
Jul 2 |
N-Power Medicine partners with MSD to expand access to oncology clinical trials
|
Jul 1 |
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
|
Jul 1 |
What's Going On With Merck Stock On Monday?
|
Jul 1 |
Orion to hand over exclusive rights to MSD for prostate cancer therapy
|
Jul 1 |
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
|
Jul 1 |
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
|
Jul 1 |
10 clinical trials to watch in the second half of 2024
|
Jun 30 |
Questor: This ‘wonder drug’ firm is being backed by top fund managers
|